This study will determine whether 8 weekly monitoring of hemoglobin and iron parameters in the correction phase of NeoRecormon therapy in patients with renal anemia is as safe and effective as 4 weekly monitoring. Patients with chronic kidney disease will receive NeoRecormon at a dose aimed at achieving and maintaining a Hb level of 110-130g/L. They will be randomized into one of two schedules for monitoring hemoglobin levels and iron parameters, either 4 weekly or 8 weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 inidividuals.

Inclusion Criteria:

• adult patients, 18-80 years of age;
• stage 3-4 chronic kidney disease (eGFR 15-60mL/min);
• Hb <100g/L, TSAT>=20%, and ferritin >=100 mcg/L at screening.

Exclusion Criteria:

• anticipating to go on renal replacement therapy;
• anticipating a living related-donor kidney transplant, or a prior recipient of a kidney transplant;
• uncontrolled hypertension;
• congestive heart failure;
• active bleeding or red blood cell transfusions in 8 weeks prior to screening; systematic hematological disease.